Omeros Corp. (OMER) said a study of its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% showed that the drug can reduce the use of the opioid fentanyl during cataract surgery and also alleviates surgical pain.
Omidria is used to prevent miosis (pupil constriction) and to reduce postoperative pain for adults and pediatric patients who are undergoing cataract or lens replacement surgery.
The study was conducted to assess the effect of Omidria compared with epinephrine on perioperative fentanyl use and pain in 60 patients undergoing cataract surgery. The study found that patients in the Omidria group were more likely not to need fentanyl in comparison with epinephrine patients. Pain scores were also lower in the Omidria group than in the epinephrine group.